Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
British Journal of Dermatology2020Vol. 184(3), pp. 437–449
Citations Over TimeTop 1% of 2020 papers
Andreas Wollenberg, Andrew Blauvelt, Emma Guttman‐Yassky, Margitta Worm, Charles Lynde, J.‐P. Lacour, Lynda Spelman, Norito Katoh, Hidehisa Saeki, Yves Poulin, Aleksandra Lesiak, Leon Kircik, S.H. Cho, Pedro Herranz, Michael J. Cork, Ketty Peris, Louise Abildgaard Steffensen, B K Bang, Alexandra Kuznetsova, T.N. Jensen, Marie Louise Østerdal, Eric L. Simpson, the ECZTRA 1 and ECZTRA 2 study investigators
Abstract
Tralokinumab monotherapy was superior to placebo at 16 weeks of treatment and was well tolerated up to 52 weeks of treatment.
Related Papers
- → Atopic dermatitis phenotypes and the need for personalized medicine(2017)154 cited
- → New Directions in Understanding Atopic March Starting from Atopic Dermatitis(2022)42 cited
- → Μελέτη της πολυπαραγοντικής αναλγησίας στο μετεγχειρητικό πόνο μετά από λαπαροσκοπική χολοκυστεκτομή(2014)
- Expression and significance of interleukin 4 in patients with atopic dermatitis(2009)
- → A Systemic Review of Dupilumab Efficacy and Safety by Phenotypic Variations of Atopic Dermatitis(2021)